1 Abstract
Tracking the dynamics and spread of COVID-19 is critical to mounting an effective response to the pandemic. In the absence of randomized representative serological surveys, many SARS-CoV-2 serosurveillance studies have relied on convenience sampling to estimate cumulative incidence. One common approach is to recruit at frequently visited community locations (“venue-based” sampling), but the sources of bias and uncertainty associated with this strategy are still poorly understood. Here, we used data from a venue-based community serosurveillance study, GPS-estimated foot traffic data, and data on confirmed COVID-19 cases to report an estimate of cumulative incidence in Somerville, Massachusetts, and a methodological strategy to quantify and reduce uncertainty in serology-based cumulative incidence estimates obtained via convenience sampling. The mismatch between the geographic distribution of participants’ home locations (the “participant catchment distribution”) and the geographic distribution of infections is an important determinant of uncertainty in venue-based and other convenience sampling strategies. We found that uncertainty in cumulative incidence estimates can vary by a factor of two depending how well the participant catchment distribution matches the known or expected geographic distribution of prior infections. GPS-estimated business foot traffic data provides an important proxy measure for the participant catchment area and can be used to select venue locations that minimize uncertainty in cumulative incidence.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the Morris-Singer Foundation and NIH T32AI007061. The funding bodies had no role in the study design and implementation, data analysis, or manuscript preparation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was designated minimal risk human subjects research and approved by institutional review boards at Massachusetts General Hospital and the Harvard T.H. Chan School of Public Health (Protocol number:2020P001081).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data used in this study are available either via publicly available sources (for business foot traffic data) or via request of the study authors (serological data).
